CXCL12 and pancreatic ductal adenocarcinoma: For instance, when we focus on the chemokine signal in the adhesion process, the SDF1-CXCR4 axis is a druggable target, and preclinical trials using blocking reagents are underway on other malignancies, including pancreatic ductal adenocarcinoma [94].